FDA clears Roche’s Alzheimer’s blood test for U.S. use
The story in brief
The FDA has cleared Roche's Elecsys pTau217 blood test for Alzheimer’s disease, following its European approval in May. The test, which identifies potential Alzheimer’s-related brain changes, will be offered by Labcorp and Quest Diagnostics, expanding U.S. access. It can run on existing Roche analysers, offering a simpler alternative to costly and invasive current methods like PET scans and cerebrospinal fluid testing.